Key Facts
This company profile is a search result of implisense.com
Website
https://ursapharm.de/Phone
+49 681 50100Products and Services
ArzneimittelBromelainNahrungsergänzungsmittelSize (Revenue & Employees)
Large companyBalance sheet total
300 M €Legal Form
GmbHCommercial Register
SaarbrückenHRB 18141
Legal Entity Identifier (LEI)
5299003ZSSI0J5F5P346Incorporation
Capital Stock
Historical Names
Order Implisense Plus now for full company profiles and complete functionality! You will then have access to our GDPR-compliant real-time contact search, full annual reports, all search filters, complete search results and integrated AI analyses of the business model and management report.
- Real-time search for contact persons
- Complete annual reports
- More search filters and results
Customer Relationship Intelligence: The Key to Optimizing your Sales Processes
Use our AI-powered assistants to identify the right companies, track current developments and market changes, reach relevant decision-makers and perfect your sales strategy with data-based insights. All seamlessly integrated into your CRM.
- Find the right companies
- Keep an eye on your target companies
- Reach the right decision-makers
- Increase your closing rate
Executive Summary
Implisense Assist gives you the opportunity to use AI to find out about companies via chat, analyze them and much more. We from the Implisense team also provide you with ready-made analyses, e.g., an executive summary and a financial analysis. Just try it out for yourself!
Implisense Plus
Contacts
Search for contact persons and decision-makers in real time with our AI-supported GDPR-compliant solution.
- Frank Holzer
- Dominik Holzer
Key Figures
AnalysisAnalysis with Implisense Assist
Create an AI analysis of the balance sheet with Implisense Assist.
See directly all available financial statements of this company.
+7.6%
€ 1.00
€ 1.00
€ 1.00
€ 1.00
€ 295,127,521.00
€ 317,674,182.00
The key figures on balance sheet total, revenue, profit and number of employees were generated by a fully automatic extraction from published annual financial statements. The last published balance sheet total of the URSAPHARM Arzneimittel GmbH is 2023 at 300 M €. The difference compared to the previous year is +7.6%.
€ 1.00
€ 1.00
€ 1.00
€ 1.00
€ 1.00
€ 1.00
The key figures on balance sheet total, revenue, profit and number of employees were generated by a fully automatic extraction from published annual financial statements.
€ 1.00
€ 1.00
€ 1.00
€ 1.00
€ 1.00
€ 1.00
The key figures on balance sheet total, revenue, profit and number of employees were generated by a fully automatic extraction from published annual financial statements.
1 Employees
1 Employees
1 Employees
1 Employees
1 Employees
1 Employees
The key figures on balance sheet total, revenue, profit and number of employees were generated by a fully automatic extraction from published annual financial statements.
| Total Assets in € | 2023 | 2022 | 2021 |
|---|---|---|---|
| Fixed Assets | |||
| Current Assets | |||
| Receivables | |||
| Cash and Cash Equivalents | |||
| Sum of Total Assets |
| Total Liabilities in € | 2023 | 2022 | 2021 |
|---|---|---|---|
| Equity | |||
| Net Income | |||
| Obligations | |||
| Accruals | |||
| Sum of Total Liabilities |
Timeline
Search in real time for news and events – topic-specific, live, and contextual to the selected company.
Network
Discover connections between companies via managers, shareholdings, links or addresses here.
Register to see more connections via management and web links. Get access to an interactive network to better understand the environment of this company.
Show moreProducts & Technologies
URSAPHARM Arzneimittel GmbH is mentioned in public sources in the context of the following products and services. Arzneimittel, Bromelain and Nahrungsergänzungsmittel are the most common. The ranking list shown is without guarantee of completeness or correctness.
The following software solutions, technologies and concepts are often referenced in job postings and press releases of URSAPHARM Arzneimittel GmbH. Most frequently recognized were Software as a Service.
Dominance, Competence, Clarity
Innovation, Passion, Creativity
Harmony, Reliability, Communicatibility
Dilligence, Introspection, Thoroughness
The 4 Color Scheme separates people and their personalities into four groups. URSAPHARM Arzneimittel GmbH emphasizes the following character types in their external communications and job advertisements.
You can find more information on the FAQ page.
Information for Job Seekers
The following job advertisements could be detected on job portals and public webpages of URSAPHARM Arzneimittel GmbH.
Based on job advertisements of URSAPHARM Arzneimittel GmbH, the following specific requirements for job seekers were identified more frequently. Specific requirements can be found in the latest published job advertisements.
Methodische Kompetenz
Persönliche Kompetenz
Soziale Kompetenz
The following additional requirements were identified more frequently. These may vary and are provided for guidance.
- Shift work
The following benefits were repeatedly recognized in job postings of URSAPHARM Arzneimittel GmbH. This data is supplied without liability and intended for orientation purposes only.
The following types of employment were recognized in job advertisements. The types of employment can vary depending on the position and serve as a guide.
- Ausbildung
Register quickly and easily for a free Implisense account. Registered users have access to extended company profiles and receive more comprehensive search results. If you register with a business email address, we will also set up a free 7-day trial for Implisense Plus in a timely manner.
- Richer Company Profiles
- Expanded Search Results
- Personal Favourites
Social Media
Facebook
Due to the cookie preference you have selected, no third-party content will be displayed. You can subsequently enable them and thus allow corresponding cookies. Further information can be found in the data protection declaration.
Allow third-party content
URSAPHARM Arzneimittel GmbH is active on these social media channels.